Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D | P28221 | 4/20 | 0.52 |
| ▸ | HTR1B | P28222 | 3/20 | 0.52 |
| ▸ | ADRA2C | P18825 | 9/20 | 0.51 |
| ▸ | ADRA1A | P35348 | 6/20 | 0.51 |
| ▸ | CFB | P00751 | 5/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | ADRA2A | P08913 | 8/20 | 0.46 |
| ▸ | ADRA2B | P18089 | 8/20 | 0.46 |
| ▸ | ADRA1D | P25100 | 5/20 | 0.44 |
| ▸ | ADRA1B | P35368 | 5/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.44 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | HRH2 | P25021 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5611436 | 0.84 | ADRA2A (0.58) | HTR1DHTR1BADRA2CADRA1ACFB | |
| SCHEMBL5442648 | 0.77 | HTR1D (0.64) | HTR1DHTR1BADRA2CADRA1ACFB | |
| SCHEMBL5612487 | 0.77 | ADRA2A (0.56) | HTR1DHTR1BADRA2CADRA1ACFB | |
| SCHEMBL4761560 | 0.75 | HTR1D (0.75) | HTR1DHTR1BADRA2CADRA1ACFB | |
| SCHEMBL5612448 | 0.75 | ADRA2A (0.61) | HTR1DADRA2CADRA1AADRA2AADRA2B | |
| SCHEMBL11182818 | 0.75 | ADRA2C (0.65) | HTR1DHTR1BADRA2CADRA1ACFB | |
| SCHEMBL17887765 | 0.74 | HTR1D (0.79) | HTR1DHTR1BADRA2CADRA1ACFB | |
| Hydrochloric Acid SCHEMBL11857722 | 0.73 | ADRA2C (0.66) | HTR1DHTR1BADRA2CADRA1ACFB | |
| SCHEMBL14380996 | 0.70 | ADRA2A (0.65) | HTR1DADRA2CADRA1AADRA2AADRA2B | |
| Romifidine SCHEMBL246009 | 0.69 | ADRA2C (0.56) | HTR1DHTR1BADRA2CADRA1ACFB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2007509897-A | — | — | 2007-04-19 | — | — | JP | claimed |
| EP-1682110-A1 | PHARMACEUTICAL COMPOSITION CONSISTING OF A BETA-3 ADRENOCEPTOR AGONIST AND AN ALPHA AGONIST | Boehringer Ingelheim International GmbH (DE) | 2006-07-26 | — | — | EP | claimed |
| US-20050154041-A1 | Pharmaceutical composition consisting of a beta-3-adrenoceptor agonist and alpha-agonist | BOEHRINGER INGELHEIN INTERNATIONAL GMBH (DE) | 2005-07-14 | — | — | US | claimed |
| WO-2005046664-A1 | PHARMACEUTICAL COMPOSITION CONSISTING OF A BETA-3 ADRENOCEPTOR AGONIST AND AN ALPHA AGONIST | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-05-26 | — | — | WO | claimed |
| EP-1682110-A1 | PHARMACEUTICAL COMPOSITION CONSISTING OF A BETA-3 ADRENOCEPTOR AGONIST AND AN ALPHA AGONIST | Boehringer Ingelheim International GmbH (DE) | 2006-07-26 | — | — | EP | disclosed |
| US-20050154041-A1 | Pharmaceutical composition consisting of a beta-3-adrenoceptor agonist and alpha-agonist | BOEHRINGER INGELHEIN INTERNATIONAL GMBH (DE) | 2005-07-14 | — | — | US | disclosed |
| WO-2005046664-A1 | PHARMACEUTICAL COMPOSITION CONSISTING OF A BETA-3 ADRENOCEPTOR AGONIST AND AN ALPHA AGONIST | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050154041-A1 | Pharmaceutical composition consisting of a beta-3-adrenoceptor agonist and alpha-agonist | ADRB3, ADRB2, ADRB1 | HTR1D 216/4885HTR1B 188/4885ADRA2C 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.